

Henk-Jan Guchelaar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5786549/henk-jan-guchelaar-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

356 papers	13,545 citations	55 h-index	104 g-index
373 ext. papers	16,241 ext. citations	4.8 avg, IF	6.38 L-index

#	Paper	IF	Citations
356	Contribution of Common and Rare Genetic Variants in CEP72 on Vincristine-Induced Peripheral Neuropathy in Brain Tumor Patients.. <i>British Journal of Clinical Pharmacology</i> , 2022 ,	3.8	1
355	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.. <i>European Journal of Cancer</i> , 2022 , 162, 148-157	7.5	2
354	Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?. <i>Frontiers in Pharmacology</i> , 2022 , 13, 826004	5.6	0
353	Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.. <i>Scientific Reports</i> , 2022 , 12, 4206	4.9	2
352	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 803935	5.6	0
351	Pharmacogenetics: optimising prescribing in primary care. <i>The Prescriber</i> , 2022 , 33, 10-13	0.4	0
350	Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury. <i>Journal of Personalized Medicine</i> , 2022 , 12, 892	3.6	0
349	Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. <i>Pharmacogenomics Journal</i> , 2021 ,	3.5	1
348	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. <i>European Journal of Human Genetics</i> , 2021 ,	5.3	3
347	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	5
346	Learning From Consultations Conducted by Community Pharmacists in Northern Ireland for Nonprescription Sildenafil: A Qualitative Study Using the Theoretical Domains Framework. <i>Sexual Medicine</i> , 2021 , 9, 100440	2.7	0
345	An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data. <i>Family Practice</i> , 2021 , 38, 292-298	1.9	2
344	Detecting DPD deficiency: when perfect is the enemy of good. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 717-719	3.5	0
343	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1201-1215	6.2	2
342	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. <i>Mycoses</i> , 2021 , 64, 1111-1116	5.2	1
341	Liver and kidney function in patients with Covid-19 treated with remdesivir. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4450-4454	3.8	7
340	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3574-3574	2.2	3

339	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. <i>Drug Discovery Today</i> , 2021 , 26, 2527-2546	8.8	1
338	3D printed furosemide and sildenafil tablets: Innovative production and quality control. <i>International Journal of Pharmaceutics</i> , 2021 , 603, 120694	6.5	2
337	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 89-102	6.2	2
336	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 191-203	6.2	3
335	Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 591-604	6.1	7
334	Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2907-2925	3.8	6
333	Toward predicting CYP2D6-mediated variable drug response from gene sequencing data. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	9
332	Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021 , 12, 693453	5.6	6
331	Substrate specificity of CYP2D6 genetic variants. <i>Pharmacogenomics</i> , 2021 , 22, 1081-1089	2.6	1
330	Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool. <i>Scientific Reports</i> , 2021 , 11, 19084	4.9	
329	Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 99.e1-99.e1		2
328	Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. <i>Scientific Reports</i> , 2021 , 11, 415	4.9	3
327	Respiratory Adherence Care Enhancer Questionnaire: Identifying Self-Management Barriers of Inhalation Corticosteroids in Asthma.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 767092	5.6	
326	Technologies for Pharmacogenomics: A Review. <i>Genes</i> , 2020 , 11,	4.2	7
325	An Electronic Health Record Text Mining Tool to Collect Real-World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 644-652	6.1	5
324	Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 1141-1152	3.5	7
323	Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
322	RAINFOREST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. <i>Bioinformatics</i> , 2020 , 36, i601-i609	7.2	6

321	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 617-627	6.1	9
320	A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. <i>Biomedical Chromatography</i> , 2020 , 34, e4732	1.7	2
319	Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. <i>Clinical and Translational Science</i> , 2020 , 13, 116-124	4.9	177
318	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>European Journal of Human Genetics</i> , 2020 , 28, 508-517	5.3	51
317	Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. <i>Frontiers in Pharmacology</i> , 2020 , 11, 567048	5.6	12
316	Precision Medicine Using Pharmacogenomic Panel-Testing. <i>Advances in Molecular Pathology</i> , 2020 , 3, 131-142	0.3	
315	Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020 , 11, 577968	5.6	1
314	Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2020 , 141, 9-20	7.5	17
313	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020 , 30, 131-144	1.9	10
312	Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	36
311	Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in and and Methotrexate Levels and Toxicities. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1241	5.6	3
310	Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. <i>Pharmacogenomics Journal</i> , 2020 , 20, 159-168	3.5	7
309	Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1925-1931	3.6	3
308	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2019 , 20, 85-93	2.6	7
307	Adverse drug reactions on sexual functioning: a systematic overview. <i>Drug Discovery Today</i> , 2019 , 24, 890-897	8.8	4
306	Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 838-845	1.5	12
305	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , 2019 , 19, 473-479	3.5	2
304	Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1984-1985	2	

303	A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. <i>European Journal of Human Genetics</i> , 2019 , 27, 1532-1541	5.3	21
302	Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. <i>Genes</i> , 2019 , 10,	4.2	30
301	Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2033-2044	3.8	7
300	Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. <i>BMC Medicine</i> , 2019 , 17, 110	11.4	32
299	Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 523-536	3.8	36
298	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1055-1061	2.4	12
297	Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 866-873	6.1	43
296	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - AuthorsMeply. <i>Lancet Oncology, The</i> , 2019 , 20, e67	21.7	1
295	Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 636-646	2.2	52
294	The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples. <i>Scientific Reports</i> , 2019 , 9, 2495	4.9	4
293	A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 720-737	4.5	36
292	One non-believer: Response to "Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing". <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 126, 7	3.1	0
291	Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 116-120	2.2	4
290	Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 147-148	2.2	1
289	A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019 , 107, 60-67	7.5	30
288	Confirmation practice in pharmacogenetic testing; how good is good enough?. <i>Clinica Chimica Acta</i> , 2019 , 490, 77-80	6.2	2
287	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 2312-2318	12.9	44
286	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 795-801	6.1	38

285	A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. <i>Pharmacogenomics</i> , 2018 , 19, 311-319	2.6	9
284	A Genetic Polymorphism in Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 2350-2356	12.9	7
283	A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1575-1586	3.8	8
282	Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018 , 25, 893-898	8.6	37
281	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 770-777	6.1	161
280	A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. <i>Cytotherapy</i> , 2018 , 20, 769-778	4.8	13
279	SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2018 , 19, 613-619	2.6	2
278	Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. <i>Scientific Reports</i> , 2018 , 8, 5250	4.9	13
277	EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. <i>Drug Discovery Today</i> , 2018 , 23, 1328-1333	8.8	17
276	Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. <i>Pharmacogenomics Journal</i> , 2018 , 18, 49-55	3.5	6
275	The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. <i>Pharmacogenomics Journal</i> , 2018 , 18, 160-166	3.5	9
274	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 599-618	6.1	113
273	Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 3-8	2.6	
272	Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 455-473	6.2	11
271	Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. <i>Pharmacological Research</i> , 2018 , 128, 122-129	10.2	6
270	Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2761-2769	3.8	13
269	Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 179-182	3.5	7
268	Genetic polymorphisms of 3Muntranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 401-411	4.4	12

267	Implementation of Pharmacogenomics in Everyday Clinical Settings. <i>Advances in Pharmacology</i> , 2018 , 83, 219-246	5.7	17
266	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 523-523	2.2	2
265	The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 114, 24-29	5.1	2
264	Patients' Beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 167-173	2.3	8
263	Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. <i>PLoS ONE</i> , 2018 , 13, e0208080	3.7	3
262	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , 2018 , 9,	4.2	5
261	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018 , 104, 210-218	7.5	5
260	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 1459-1467	21.7	139
259	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2889-2902	3.8	39
258	The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review. <i>Drug Discovery Today</i> , 2018 , 23, 1312-1318	8.8	23
257	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. <i>Pharmacogenomics Journal</i> , 2017 , 17, 42-46	3.5	14
256	Pharmaceutical pictograms for low-literate patients: Understanding, risk of false confidence, and evidence-based design strategies. <i>Patient Education and Counseling</i> , 2017 , 100, 966-973	3.1	10
255	A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. <i>Pharmacogenomics</i> , 2017 , 18, 215-225	2.6	26
254	Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 529.e9-529.e16	2.8	6
253	Understanding clinical development of chimeric antigen receptor T cell therapies. <i>Cytotherapy</i> , 2017 , 19, 703-709	4.8	7
252	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 227-231	1.9	4
251	Population pharmacokinetics of lenalidomide in multiple myeloma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 189-200	3.5	10
250	Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017 , 6, 604-613	4.5	11

249	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 341-358	6.1	157
248	Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. <i>Acta Oncologica</i> , 2017 , 56, 582-589	3.2	22
247	Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. <i>Human Mutation</i> , 2017 , 38, 310-316	4.7	39
246	Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 391-402	6.1	22
245	High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. <i>British Journal of Haematology</i> , 2017 , 179, 772-780	4.5	24
244	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017 , 86, 226-232	7.5	11
243	Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. <i>Current Pharmaceutical Biotechnology</i> , 2017 , 18, 204-209	2.6	22
242	Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 698-707	5.6	43
241	Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1589-1598	2.8	28
240	Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 953-963	6.1	20
239	More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1873-1881	4.5	15
238	The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , 2017 , 18, 1125-1132	2.6	13
237	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2017 , 18, 945-953	2.6	4
236	Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1247-1252	2.8	45
235	Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 175-184	1.5	36
234	Treatment Algorithm for Homozygous or Compound Heterozygous Variant Allele Carriers With Low-Dose Capecitabine.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-10	3.6	3
233	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017 , 8, 1204-1212	3.3	5
232	The role of pharmacogenetics in capecitabine efficacy and toxicity. <i>Cancer Treatment Reviews</i> , 2016 , 50, 9-22	14.4	47

231	Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. <i>British Journal of Cancer</i> , 2016 , 115, 1335-1342	8.7	27
230	Making sense of big data in health research: Towards an EU action plan. <i>Genome Medicine</i> , 2016 , 8, 71	14.4	146
229	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 63-71	3.5	22
228	Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2016 , 18, 3	8.3	21
227	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 243-7	1.9	32
226	Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 227-37	3.8	9
225	Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 163-74	2.8	35
224	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 605-18	3.8	12
223	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016 , 54, 40-48	7.5	82
222	Prospective study evaluating the effect of impaired tamoxifen metabolism on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 523-523	2.2	4
221	Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial. <i>Anesthesia and Analgesia</i> , 2016 , 123, 587-96	3.9	19
220	Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 553-61	3.8	18
219	The role of pharmacogenetics in the treatment of osteosarcoma. <i>Drug Discovery Today</i> , 2016 , 21, 1775-1786	8.6	47
218	Clinical development of gene- and cell-based therapies: overview of the European landscape. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016 , 3, 16073	6.4	25
217	Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. <i>Pharmacogenomics</i> , 2016 , 17, 721-9	2.6	17
216	Response: Limited sampling strategies for once daily tacrolimus exposure monitoring. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 775-6	2.8	
215	Development of cell therapy medicinal products by academic institutes. <i>Drug Discovery Today</i> , 2016 , 21, 1206-12	8.8	19
214	Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. <i>Cytotherapy</i> , 2016 , 18, 797-805	4.8	23

213	A brighter future for the implementation of pharmacogenomic testing. <i>European Journal of Human Genetics</i> , 2016 , 24, 1658-1660	5.3	15
212	Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 1372-1379	2.3	38
211	Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015 , 149, 907-17.e7	13.3	121
210	Pharmacogenetics in electroconvulsive therapy and adjunctive medications. <i>Pharmacogenomics</i> , 2015 , 16, 1015-31	2.6	1
209	FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2015 , 16, 373-81	2.6	18
208	Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 47-52	3.5	5
207	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. <i>European Urology</i> , 2015 , 68, 621-9	10.2	55
206	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , 2015 , 21, 3436-41	12.9	29
205	Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 58-65	3.2	18
204	Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015 , 33, 1242-7	4.3	21
203	Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. <i>Pharmacogenomics</i> , 2015 , 16, 1277-86	2.6	53
202	Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia. <i>Pharmacogenomics</i> , 2015 , 16, 1267-76	2.6	4
201	GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population. <i>Pharmacogenomics</i> , 2015 , 16, 681-7	2.6	8
200	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1477-84	2.8	18
199	Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review. <i>Cancer Treatment Reviews</i> , 2015 , 41, 935-50	14.4	88
198	High-quality genotyping data from formalin-fixed, paraffin-embedded tissue on the drug metabolizing enzymes and transporters plus array. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 4-9	5.1	9
197	Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2183-7	2.4	25
196	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. <i>Drug Discovery Today</i> , 2015 , 20, 18-36	8.8	59

195	Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 279-88	1.9	3
194	Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Anti-Cancer Drugs</i> , 2015 , 26, 872-7	2.4	12
193	The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 501-7	3.2	11
192	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1344-50	2.9	22
191	Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 331-8	3.2	41
190	Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015 , 10, e0131091	3.7	8
189	Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. <i>International Journal of Endocrinology</i> , 2015 , 2015, 348124	2.7	32
188	Sirolimus and everolimus in kidney transplantation. <i>Drug Discovery Today</i> , 2015 , 20, 1243-9	8.8	83
187	Patients' preferences for visuals: differences in the preferred level of detail, type of background and type of frame of icons depicting organs between literate and low-literate people. <i>Patient Education and Counseling</i> , 2015 , 98, 226-33	3.1	15
186	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4548-4548	2.2	
185	Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 429-33	3.5	9
184	Pharmacogenetic biomarkers for predicting drug response. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 723-35	3.8	7
183	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014 , 506, 376-81	50.4	1426
182	Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 383-5	6.1	11
181	Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 1303-6	3.5	11
180	Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 599-606	4.4	27
179	Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. <i>Internal and Emergency Medicine</i> , 2014 , 9, 481-2	3.7	2
178	Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. <i>Drug Discovery Today</i> , 2014 , 19, 1572-86	8.8	47

177	Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. <i>PLoS ONE</i> , 2014 , 9, e87645	3.7	24
176	Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014 , 3, e100	4.5	55
175	Pharmacogenetics of taste: turning bitter pills sweet?. <i>Pharmacogenomics</i> , 2014 , 15, 111-9	2.6	3
174	Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. <i>European Journal of Endocrinology</i> , 2014 , 171, 677-83	6.5	10
173	Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. <i>Anti-Cancer Drugs</i> , 2014 , 25, 140-9	2.4	109
172	Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 465-72	3.2	29
171	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014 , 759, 37-44	3.3	10
170	CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 171-9	4.4	9
169	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 87-96	3.5	18
168	Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. <i>PLoS ONE</i> , 2014 , 9, e112201	3.7	24
167	Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. <i>PLoS ONE</i> , 2014 , 9, e115869	3.7	40
166	Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11074-11074	2.2	
165	Treosulfan-Based Conditioning in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Study on Pharmacokinetics and Early Clinical Outcomes. <i>Blood</i> , 2014 , 124, 3865-3865	2.2	
164	Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. <i>Investigational New Drugs</i> , 2013 , 31, 1087-94	4.3	110
163	Breath tests to phenotype drug disposition in oncology. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 919-26	6.2	4
162	The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 833-54	6.2	22
161	Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. <i>Pharmacogenomics</i> , 2013 , 14, 2005-12	2.6	23
160	Pharmacogenetics in transplant patients: mind the mix. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 443-4	6.1	2

159	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1375-81	2.4	79
158	Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. <i>Clinical Therapeutics</i> , 2013 , 35, 1946-54	3.5	63
157	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 937, 33-43	3.2	59
156	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. <i>Pharmacogenomics</i> , 2013 , 14, 63-73	2.6	17
155	Evaluation of rule effectiveness and positive predictive value of clinical rules in a Dutch clinical decision support system in daily hospital pharmacy practice. <i>Artificial Intelligence in Medicine</i> , 2013 , 59, 15-21	7.4	16
154	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013 , 167, 2882-8	3.2	23
153	Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1437-44	2.8	16
152	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , 2013 , 9, e1003394	6	127
151	Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 675-83	1.9	14
150	A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 631-5	1.9	4
149	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013 , 45, 468-9	36.3	20
148	Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2013 , 14, 1683-90	2.6	22
147	Non-homologous end-joining pathway associated with occurrence of myocardial infarction: gene set analysis of genome-wide association study data. <i>PLoS ONE</i> , 2013 , 8, e56262	3.7	13
146	CYP3A4 phenotyping with midazolam to predict sunitinib exposure.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2592-2592	2.2	1
145	Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e22152-e22152	2.2	1
144	Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 594-594	2.2	
143	The influence of gastrointestinal resection on sunitinib exposure in GIST patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10547-10547	2.2	
142	Safety and efficacy of the addition of simvastatin to panitumumab in KRAS mutant metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14558-e14558	2.2	

141	Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 595-595	2.2	
140	CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 597-597	2.2	
139	Safety and efficacy of the addition of simvastatin to cetuximab in KRAS mutant metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14586-e14586	2.2	
138	Liposomal drug formulations in cancer therapy: 15 years along the road. <i>Drug Discovery Today</i> , 2012 , 17, 160-6	8.8	196
137	Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 83-8	2.8	12
136	Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 467-80	6.2	49
135	Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. <i>Pharmacogenomics</i> , 2012 , 13, 1087-94	2.6	27
134	Phenotyping drug disposition in oncology. <i>Cancer Treatment Reviews</i> , 2012 , 38, 715-25	14.4	8
133	A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. <i>European Heart Journal</i> , 2012 , 33, 165-75	9.5	60
132	Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 363-70	2.8	28
131	Lapatinib for advanced or metastatic breast cancer. <i>Oncologist</i> , 2012 , 17, 536-42	5.7	41
130	Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 3091-3097	10.3	8
129	Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians. <i>International Journal of Biological Markers</i> , 2012 , 27, 34-8	2.8	3
128	Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 139-45	3.5	17
127	Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10518-10518	2.2	
126	A computerized adverse drug event alerting system using clinical rules: a retrospective and prospective comparison with conventional medication surveillance in the Netherlands. <i>Drug Safety</i> , 2011 , 34, 233-42	5.1	23
125	Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3455-68	12.9	138
124	Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. <i>Journal of Immunotherapy</i> , 2011 , 34, 307-19	5	36

123	Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 461-8	1.9	7
122	Pharmacogenetics: from bench to byte--an update of guidelines. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 662-73	6.1	684
121	Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. <i>Investigational New Drugs</i> , 2011 , 29, 137-43	4.3	14
120	Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. <i>Investigational New Drugs</i> , 2011 , 29, 953-62	4.3	14
119	Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , 2011 , 33, 33-43	2.3	39
118	Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 695-703	3.5	36
117	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2011 , 22, 1147-1153	10.3	30
116	Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. <i>Oncologist</i> , 2011 , 16, 1239-49	5.7	75
115	Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>European Journal of Endocrinology</i> , 2011 , 164, 621-6	6.5	76
114	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. <i>Clinical Cancer Research</i> , 2011 , 17, 620-9	12.9	130
113	Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 519-29	2.8	33
112	Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 1168-76	2.8	21
111	Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. <i>Clinical Cancer Research</i> , 2011 , 17, 5668-73	12.9	77
110	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011 , 12, 159-70	2.6	58
109	Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1B gene. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 50, 279-84	5.9	7
108	Reply to R. Ferraldeschi et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e586-e586	2.2	
107	Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. <i>Pharmacogenomics</i> , 2010 , 11, 1011-7	2.6	11
106	Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2423-9	2.2	126

105	Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 746-9	5.1	29
104	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. <i>Pharmacogenomics</i> , 2010 , 11, 163-75	2.6	57
103	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1829-34	7.5	67
102	The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. <i>European Journal of Internal Medicine</i> , 2010 , 21, 293-6	3.9	10
101	Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. <i>Pharmacogenomics</i> , 2010 , 11, 1517-23	2.6	21
100	Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. <i>Cytotherapy</i> , 2010 , 12, 933-44	4.8	24
99	Pharmacogenetics in oncology: a promising field. <i>Current Pharmaceutical Design</i> , 2010 , 16, 155-63	3.3	12
98	Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 413-9	3.2	26
97	Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. <i>Haematologica</i> , 2010 , 95, 1943-51	6.6	56
96	Explaining variability in ciclosporin exposure in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 579-90	2.8	27
95	Therapeutic modulation of k-ras signaling in colorectal cancer. <i>Drug Discovery Today</i> , 2010 , 15, 502-16	8.8	27
94	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4406-12	2.2	161
93	Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. <i>Annals of Oncology</i> , 2009 , 20, 358-64	10.3	52
92	Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 15-21	12.9	67
91	Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. <i>Drug Discovery Today</i> , 2009 , 14, 837-44	8.8	8
90	Pharmacogenetics in chemotherapy of colorectal cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2009 , 23, 257-73	2.5	10
89	Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1245-51	2.8	23
88	Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2620-7	4.3	37

87	The Dutch vision of clinical pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 366-8	6.1	5
86	Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cancer Epidemiology</i> , 2009 , 33, 391-5	2.8	18
85	Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2009 , 45, 572-8	7.5	48
84	Application of the Bow-Tie model in medication safety risk analysis: consecutive experience in two hospitals in the Netherlands. <i>Drug Safety</i> , 2009 , 32, 663-73	5.1	28
83	Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. <i>American Journal of Hypertension</i> , 2009 , 22, 1295-302	2.3	11
82	Clinical pharmacokinetics of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2009 , 35, 692-706	14.4	316
81	Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 935-44	1.9	45
80	Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 187-97	3.2	103
79	Detailed analysis of IFN γ response upon activation permits efficient isolation of cytomegalovirus-specific CD8 $^{+}$ T cells for adoptive immunotherapy. <i>Journal of Immunotherapy</i> , 2009 , 32, 513-23	5	10
78	Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 46-51		86
77	Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. <i>Journal of Clinical Oncology</i> , 2009 , 27, CRA509-CRA509	2.2	3
76	Pharmacogenetics: from bench to byte. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 781-7	6.1	158
75	Perinatal dioxin exposure, cytochrome P-450 activity, liver functions and thyroid hormones at follow-up after 7-12 years. <i>Chemosphere</i> , 2008 , 70, 1865-72	8.4	12
74	Clinical and pharmacogenetic factors associated with irinotecan toxicity. <i>Cancer Treatment Reviews</i> , 2008 , 34, 656-69	14.4	68
73	Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. <i>Clinical Cancer Research</i> , 2008 , 14, 8308-13	12.9	19
72	Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2828-34	5.6	45
71	Use of plasmid-derived external quality control samples in pharmacogenetic testing. <i>Pharmacogenomics</i> , 2008 , 9, 1261-6	2.6	10
70	Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 504-10	3.2	68

69	Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 1021-6	2.8	11
68	Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2008 , 22, 1368-73	1.7	0
67	Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation. <i>Blood</i> , 2008 , 112, 3904-3904	2.2	
66	Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2007 , 8, 141-50	2.6	54
65	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1765-75		193
64	Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2007 , 31, 1545-51	2.7	3
63	Preventing adverse drug events in hospital practice: an overview. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 1129-35	2.6	36
62	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. <i>Drug Discovery Today</i> , 2007 , 12, 125-31	8.8	52
61	Pharmacogenetics of EGFR and VEGF inhibition. <i>Drug Discovery Today</i> , 2007 , 12, 1054-60	8.8	40
60	Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. <i>Pharmacogenomics</i> , 2007 , 8, 159-76	2.6	18
59	Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 181-7	2.8	10
58	Is rectal administration an alternative route for imatinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 60, 623-4	3.5	5
57	Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. <i>Clinical Cancer Research</i> , 2007 , 13, 7394-400	12.9	88
56	Translating pharmacogenomics: challenges on the road to the clinic. <i>PLoS Medicine</i> , 2007 , 4, e209	11.6	120
55	Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity. <i>Current Cancer Drug Targets</i> , 2007 , 7, 504-9	2.8	20
54	Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1197-210	4	14
53	Pharmacogenetics in the future treatment of rheumatology. <i>Future Rheumatology</i> , 2007 , 2, 337-339		
52	Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2007 , 43, 459-65	7.5	21

51	Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?. <i>European Journal of Cancer</i> , 2007 , 43, 2580-9	7.5	36
50	Genetic markers of treatment response in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 369-77	4.9	12
49	Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1087-95		164
48	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2830-9		107
47	Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine. <i>Drug Development and Industrial Pharmacy</i> , 2006 , 32, 497-503	3.6	1
46	Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 444-8	5.1	8
45	Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. <i>Anti-Cancer Drugs</i> , 2006 , 17, 1099-105	2.4	22
44	Generation of GMP-Grade CMV pp65-Specific CD8+ and CD4+ Donor T Cell Lines for Treatment of CMV Reactivation after Transplantation.. <i>Blood</i> , 2006 , 108, 2931-2931	2.2	
43	Medication errors: hospital pharmacist perspective. <i>Drugs</i> , 2005 , 65, 1735-46	12.1	33
42	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 310-3	3.8	27
41	Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats. <i>Archives of Toxicology</i> , 2005 , 79, 268-76	5.8	9
40	Effect of milk thistle (<i>Silybum marianum</i>) on the pharmacokinetics of irinotecan. <i>Clinical Cancer Research</i> , 2005 , 11, 7800-6	12.9	102
39	Toxicity and Effectivity of the Experimental Cytotoxic Drug Cyclopentenyl Cytosine in NOD/scid Mice with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005 , 106, 4574-4574	2.2	
38	Outcomes of an antimicrobial control program in a Dutch hospital. <i>American Journal of Health-System Pharmacy</i> , 2004 , 61, 1702-6	2.2	2
37	Medication error due to ambiguous labelling of a commercial product. <i>International Journal of Clinical Pharmacy</i> , 2004 , 26, 10-1		7
36	Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. <i>International Journal of Clinical Pharmacy</i> , 2004 , 26, 191-2		21
35	A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis. <i>Biomedical Chromatography</i> , 2004 , 18, 723-6	1.7	16
34	The risk of cancer in users of statins. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2388-94	2.2	431

33	Cardiotoxicity of cytotoxic drugs. <i>Cancer Treatment Reviews</i> , 2004 , 30, 181-91	14.4	264
32	Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. <i>Cancer Treatment Reviews</i> , 2004 , 30, 609-41	14.4	235
31	Implementation of a computerized physician medication order entry system at the Academic Medical Centre in Amsterdam. <i>International Journal of Clinical Pharmacy</i> , 2003 , 25, 88-93		21
30	The potential role of computerisation and information technology in improving prescribing in hospitals. <i>International Journal of Clinical Pharmacy</i> , 2003 , 25, 83-7		13
29	Risk assessment in clinical pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2003 , 25, 98-103		12
28	CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. <i>European Journal of Pharmaceutical Sciences</i> , 2003 , 20, 451-7	5.1	40
27	Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. <i>Fundamental and Clinical Pharmacology</i> , 2003 , 17, 355-62	3.1	11
26	Acute Effects of High-Dose Furosemide on Residual Renal Function in CAPD Patients. <i>Peritoneal Dialysis International</i> , 2003 , 23, 339-347	2.8	32
25	Acute effects of high-dose furosemide on residual renal function in CAPD patients. <i>Peritoneal Dialysis International</i> , 2003 , 23, 339-47	2.8	35
24	5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study. <i>Fundamental and Clinical Pharmacology</i> , 2002 , 16, 39-47	3.1	9
23	Cost-Benefit Analysis of Vaccination Against Influenza of Employees from an Academic Medical Centre. <i>Disease Management and Health Outcomes</i> , 2002 , 10, 579-587		4
22	Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. <i>Fundamental and Clinical Pharmacology</i> , 2001 , 15, 419-24	3.1	7
21	Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography. <i>Biomedical Chromatography</i> , 2001 , 15, 89-94	1.7	13
20	Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Chromatography</i> , 2001 , 15, 280-6	1.7	16
19	A splinter. <i>International Journal of Clinical Pharmacy</i> , 2001 , 23, 123		1
18	Are Angiotensin II Receptor Antagonists Safe in Patients With Previous Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema?. <i>Hypertension</i> , 2001 , 37, E1	8.5	10
17	Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. <i>Journal of the Neurological Sciences</i> , 2001 , 191, 121-5	3.2	25
16	Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 676-87	3.2	23

15	Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection. <i>Biomedical Chromatography</i> , 2000 , 14, 306-10	1.7	27
14	Flucytosine: correlation between toxicity and pharmacokinetic parameters. <i>Chemotherapy</i> , 2000 , 46, 86-94	3.2	59
13	A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 2286-90	5.9	47
12	Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2000 , 46, 171-9	5.1	490
11	Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. <i>Biomedical Applications</i> , 1999 , 734, 203-10		30
10	An accelerated stability study of 5-flucytosine in intravenous solution. <i>International Journal of Clinical Pharmacy</i> , 1999 , 21, 35-9		5
9	Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. <i>Biomedical Chromatography</i> , 1999 , 13, 309-14	1.7	25
8	The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1998 , 44, 293	9.4	20
7	Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42, 77-83	3.5	58
6	Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. <i>Biomedical Applications</i> , 1998 , 720, 89-97		104
5	Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach. <i>Cancer Treatment Reviews</i> , 1997 , 23, 321-39	14.4	10
4	Apoptosis: molecular mechanisms and implications for cancer chemotherapy. <i>International Journal of Clinical Pharmacy</i> , 1997 , 19, 119-25		71
3	Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. <i>Supportive Care in Cancer</i> , 1997 , 5, 281-8	3.9	123
2	Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. <i>Clinical Oncology</i> , 1994 , 6, 40-8	2.8	55
1	A unifying model to predict variable drug response for personalised medicine		8